Hatteras Venture Partners
Hatteras Venture Partners is a North Carolina-based venture capital firm that finances biomedical companies.
Business Model:
Revenue: $6.1M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Hatteras Venture Partners Information
Geographic Data
Address: 280 S Mangum St
City: Durham
State: NC
Zip: 27701
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$598M
Social
Linkedin
Crunchbase
Metrics
3,379,412Website Global Rank
3,884Website Monthly Traffic
Twitter Followers
Description
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Contact Phone:
+19194840730
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
| 8/2020 | Qvella Corporation | Venture Round | - |
| 3/2017 | Boragen | Series A | 10M |
| 11/2018 | Kymera Therapeutics | Series B | 65M |
| 3/2016 | Bivarus | Series A | 0 |
| 9/2021 | Elligo Health Research | Series E | 0 |
| 3/2017 | HistoSonics | Series B | 0 |
| 2/2010 | HistoSonics | Series A | 0 |
| 5/2014 | Jumo Health | Series B | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 9/2021 | Qvella Corporation | Venture Round | - |
| 1/2008 | Clinipace | Series B | 0 |
| 10/2021 | GoCheck | Venture Round | 0 |
| 5/2015 | Nusirt | Series C | 0 |
| 4/2015 | Contego Medical | Series B | 0 |
| 8/2014 | Clinverse | Series C | 9.1M |
| 11/2022 | 410 Medical | Series B | 0 |
| 12/2013 | Curoverse | Seed Round | 1.5M |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2015 | Spyryx Biosciences | Series A | 18.2M |
| 6/2008 | SpineAlign Medical | Unattributed | 8.8M |
| 5/2019 | Elligo Health Research | Series C | 0 |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 4/2023 | Mercy BioAnalytics | Series A | 0 |
| 11/2022 | Boomerang Medical | Series A | 0 |
| 8/2019 | GrayBug | Series C | 80M |
| 1/2017 | Trefoil Therapeutics | Series A | 0 |
| 4/2020 | AtaCor Medical | Series B | 0 |
| 1/2022 | AN2 Therapeutics | Series B | 80M |
| 12/2021 | Tune Therapeutics | Series A | 40M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 6/2007 | Viamet Pharmaceuticals | Series A | 4M |
| 9/2011 | Clinipace | Series C | 15M |
| 5/2016 | GrayBug | Series B | 44.5M |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 2/2015 | Lysosomal Therapeutics | Series A | 20M |
| 6/2008 | ArtusLabs | Series A | 0 |
| 11/2018 | Ribometrix | Series A | 30M |
| 10/2008 | Pathfinder Therapeutics | Series A | 0 |
| 5/2014 | Lysosomal Therapeutics | Seed Round | 4.8M |
| 9/2017 | Rodin Therapeutics | Series C | 0 |
| 2/2015 | ORIG3N | Venture Round | 3.1M |
| 7/2019 | Trefoil Therapeutics | Series A | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 3/2018 | Wildflower Health | Series C | 8M |
| 3/2021 | Boston Immune Technologies &a; Therapeutics | Series A | 10M |
| 4/2017 | NeuroTronik | Series B | 0 |
| 7/2001 | Empliant | Venture Round | 500k |
| 2/2022 | Huma.AI | Series A | 0 |
| 3/2015 | GrayBug | Series A | 1.7M |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 12/2020 | Atsena Therapeutics | Series A | 0 |
| 6/2020 | Shattuck Labs | Series B | 0 |
| 12/2021 | Trefoil Therapeutics | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
| 10/2013 | G1 Therapeutics | Series A | 0 |
| 1/2015 | Clinipace | Private Equity Round | 0 |
| 2/2015 | G1 Therapeutics | Series B | 0 |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 4/2023 | Aer Therapeutics | Series A | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 12/2022 | Cardiosense | Series A | 0 |
| 10/2009 | Embrella Cardiovascular | Series B | 1.6M |
| 6/2021 | RapidPulse | Series A | 0 |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 12/2015 | ORIG3N | Series A | 0 |
| 2/2013 | Clearside Biomedical | Series A | 7.9M |
| 6/2019 | Artizan Biosciences | Series A | 0 |
| 10/2019 | 410 Medical | Series A | 8M |
| 9/2014 | Clearside Biomedical | Series B | 16M |
| 4/2017 | MATI Energy | Series A | 2.5M |
| 7/2012 | Coferon | Series B | 12M |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 7/2020 | Altis Biosystems | Seed Round | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 3/2017 | Bivarus | Series B | 0 |
| 3/2018 | Clinipace | Venture Round | 0 |
| 6/2021 | Standard Bariatrics | Series B | 35M |
| 1/2018 | NurseGrid | Venture Round | 5.7M |
| 12/2017 | Qvella Corporation | Series B | 0 |
| 3/2019 | Qvella Corporation | Venture Round | - |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 8/2022 | RapidPulse | Series A | 0 |
| 3/2022 | Wildflower Health | Venture Round | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 6/2017 | ORIG3N | Venture Round | 0 |
| 3/2021 | Artizan Biosciences | Series A | 0 |
| 6/2015 | Wildflower Health | Equity | 5M |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 4/2018 | Standard Bariatrics | Series A | 0 |
| 3/2018 | Elligo Health Research | Series B | 0 |
| 8/2015 | Medfusion | Venture Round | 3M |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 2/2017 | Artizan Biosciences | Venture Round | - |
| 6/2017 | StrideBio | Seed Round | - |
| 1/2012 | GeneCentric Therapeutics | Seed Round | - |
| 10/2015 | Qvella Corporation | Series A | 20M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2021 | NoviSci | Seed Round | - |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 1/2012 | Clearside Biomedical | Series A | 4M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 12/2018 | WalletFi | Convertible Note | 0 |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 10/2018 | Qpex Biopharma | Series A | 33M |
| 4/2020 | Atsena Therapeutics | Venture Round | 8.2M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 4/2023 | Aer Therapeutics | Series A | 0 |
| 4/2023 | Mercy BioAnalytics | Series A | 0 |
| 12/2022 | Cardiosense | Series A | 0 |
| 11/2022 | 410 Medical | Series B | 0 |
| 11/2022 | Boomerang Medical | Series A | 0 |
| 8/2022 | RapidPulse | Series A | 0 |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 3/2022 | Wildflower Health | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
